Who are FLUCON®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Voriconazole high dose, Voriconazole clinical practice, fast itraconazole tablet, ORAL VORICONAZOLE and IV Amphotericin B, Vivjoa, Cresemba.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flucon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

FLUCON® — Competitive Intelligence Brief

FLUCON® (FLUCON®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Azole antifungal. Area: Infectious Disease.

marketed Azole antifungal Fungal cytochrome P450 (lanosterol 14α-demethylase) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

FLUCON® (FLUCON®) — Military Hospital of Tunis. FLUCON® is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
FLUCON® TARGET	FLUCON®	Military Hospital of Tunis	marketed	Azole antifungal	Fungal cytochrome P450 (lanosterol 14α-demethylase)
Voriconazole high dose	Voriconazole high dose	Manjunath Prakash Pai	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
Voriconazole clinical practice	Voriconazole clinical practice	Instituto de Investigación Hospital Universitario La Paz	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
fast itraconazole tablet	fast itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
ORAL VORICONAZOLE and IV Amphotericin B	ORAL VORICONAZOLE and IV Amphotericin B	All India Institute of Medical Sciences	phase 3	Antifungal agents (triazole and polyene)	Fungal cytochrome P450 lanosterol 14α-demethylase (voriconazole); ergosterol (amphotericin B)
Vivjoa	OTESECONAZOLE	Mycovia Pharms	marketed	Azole Antifungal [EPC]	Cytochrome P450 3A4	2022-01-01
Cresemba	ISAVUCONAZONIUM	Astellas Pharma	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Azole antifungal class)

Pfizer · 3 drugs in this class
Elion Therapeutics, Inc. · 1 drug in this class
Hadassah Medical Organization · 1 drug in this class
Hatem AbuHashim · 1 drug in this class
Janssen Pharmaceutical K.K. · 1 drug in this class
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · 1 drug in this class
Military Hospital of Tunis · 1 drug in this class
Mycovia Pharmaceuticals Inc. · 1 drug in this class
Nuvation Bio Inc. · 1 drug in this class
Purdue Pharma LP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FLUCON® — Competitive Intelligence Brief. https://druglandscape.com/ci/flucon. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab